Alpha Teknova (TKNO) and Pluristyx announced that Pluristyx’s PluriFreeze cryopreservation system is available for purchase exclusively from Teknova. Teknova is a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, while Pluristyx is a leading provider of induced Pluripotent Stem Cells, including immune evading and safety-switch enabled iPSCs, and other innovative technologies designed to shorten the development lifecycle of tomorrow’s cell therapies.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TKNO:
- Teknova, Pluristyx announce collaboration over next-generation cell therapies
- Alpha Teknova’s Earnings Call: Growth Amid Challenges
- Positive Outlook for Alpha Teknova: Strong Financial Performance and Growth Potential
- Alpha Teknova: Strong Revenue Growth and Strategic Positioning Justify Buy Rating
- Alpha Teknova Reports Steady Revenue Growth in 2024
Questions or Comments about the article? Write to editor@tipranks.com